News & Updates

Chinese patients with locally advanced or metastatic, EGFR-mutated, MET-amplified non-small-cell lung cancer (NSCLC) whose disease progressed on first-line (1L) EGFR tyrosine kinase inhibitor (TKI) therapy obtain progression-free survival (PFS) benefit from the all-oral combination of savolitinib plus osimertinib vs platinum-based doublet chemotherapy, interim results of the phase III SACHI trial have shown.

A recent China study has provided further evidence on the real-world efficacy and safety of sacituzumab govitecan (SG) in HR+/HER2- and triple-negative breast cancer (TNBC) patients who have received at least three lines of prior therapy.